Safety and Immunogenicity of MF59-Adjuvanted Cell Culture–Derived A/H5N1 Subunit Influenza Virus Vaccine: Dose-Finding Clinical Trials in Adults and the Elderly

BACKGROUND: A/H5N1 influenza viruses have high pandemic potential; consequently, vaccines need to be produced rapidly. MF59® adjuvant reduces the antigen required per dose, allowing for dose sparing and more rapid vaccine availability. METHODS: Two multicenter, phase II trials were conducted to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Frey, Sharon E, Shakib, Sepehr, Chanthavanich, Pornthep, Richmond, Peter, Smith, Timothy, Tantawichien, Terapong, Kittel, Claudia, Jaehnig, Peter, Mojares, Zenaida, Verma, Bikash, Kanesa-thasan, Niranjan, Hohenboken, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446137/
https://www.ncbi.nlm.nih.gov/pubmed/30968056
http://dx.doi.org/10.1093/ofid/ofz107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446137/
https://www.ncbi.nlm.nih.gov/pubmed/30968056
http://dx.doi.org/10.1093/ofid/ofz107

Ejemplares similares